To hear about similar clinical trials, please enter your email below
Trial Title:
Elastography and Treatment of Lymphoma
NCT ID:
NCT05967975
Condition:
Elastography
Lymphoma
Conditions: Official terms:
Lymphoma
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Summary:
To determine accuracy of elastography in assessment of superficial lymph nodes response
to treatment in cases of lymphoma.
Detailed description:
Lymphomas are a heterogeneous group of malignancies that arise from the clonal
proliferation of lymphocytes. It represents approximately 5% of malignancies. Overall
survival is estimated to be 72%. (1)
Lymphomas are broadly classified into Hodgkin lymphoma (HL) (10%) and Non-Hodgkin
lymphoma (NHL) (90%).
HL is further classified into classical and non-classical types and NHL into B-cell,
T-cell and natural killer (NK) cell types. Diagnosis of lymphoma is confirmed by
histopathology (FNAC, True-cut or excisional biopsy).(2) The standard treatment of
lymphoma is chemotherapy and radiotherapy.
The modalities used for staging and follow up of lymphoma are:
- Computed Tomography (CT) chest, abdomen and pelvis.
- Positron Emission Tomography (PET/CT).
- Whole body Magnetic Resonance Imaging (MRI).(3)
Sonoelastography is a new technique that depends on the elastic properties of soft
tissues, with the idea of malignant lesions being stiffer than benign or normal tissue.
It may have a dependable role in evaluation of therapeutic response in patients with
lymphoma and can be used for follow up, the same way it has been used in different parts
of the body, such as the breast, and thyroid. To the best of our knowledge, there are few
studies concerning the role of elastography in the field of lymphoma disease.(4)
Criteria for eligibility:
Study pop:
Patients diagnosed as lymphoma , have superficial lymph nodes and not received any
treatment
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- patients who are histopathologically proven as lymphoma, not receive treatment and
have superficial lymphadenopathy.
Exclusion Criteria:
- 1-Lymphoma without superficial lymph nodes. 2-patients under treatment.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Start date:
August 2023
Completion date:
December 2025
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05967975
